Diagnósticos da América S/A (DASA) Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2021
NCT04683224
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Diagnósticos da América S/A (DASA)

Active Ingredients

Drugs in Phase 3 Trials (1)

ub-612 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1